Status:
COMPLETED
A Study to Evaluate Immunity to Varicella Zoster Virus After Immunization With V212 Vaccine or Zostavax (V212-003)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Herpes Zoster
Eligibility:
All Genders
60+ years
Phase:
PHASE1
Brief Summary
A study in two parts (Part A and Part B) to evaluate the responsiveness of various biomarkers of immunity to Varicella-Zoster Virus (VZV) following repeated immunizations with heat treated VZV vaccine...
Detailed Description
All eligible participants, regardless of treatment group, were administered three injections of the varicella antigen (VZV Skin Test reagent), once at baseline before the first vaccination, a second t...
Eligibility Criteria
Inclusion
- Participant has prior history of Varicella
- Female participants are of non-childbearing potential
Exclusion
- Participant has had a hypersensitivity reaction to any vaccine component
- Participant has a prior history of Herpes Zoster
- Participant has received any Varicella or Zoster vaccine including Zostavax
- Participant has a history of immunosuppression caused by disease, corticosteroids, cancer therapy or organ transplant
- Participant has an active cancer
- Participant has received or will receive a live virus vaccine or an inactivated virus vaccine 4 weeks prior to participating in study (with the exception of influenza vaccine)
- Participant is not bed-ridden or homebound
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00886613
Start Date
March 1 2009
End Date
December 1 2009
Last Update
October 6 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.